Halozyme Therapeutics
HALO
YETI Holdings
YETI
eBay
EBAY
4
Collegium Pharmaceutical
COLL
5
Workday
WDAY
(Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 40.97%306.59M | 39.75%1.19B | 104.17%438.72M | 0.58%273.76M | 47.10%264.59M | 15.79%217.49M | -13.25%854.75M | 3.71%214.88M | 16.56%272.18M | -25.83%179.87M |
Operating revenue | 40.97%306.59M | 39.75%1.19B | 104.17%438.72M | 0.58%273.76M | 47.10%264.59M | 15.79%217.49M | -13.25%854.75M | 3.71%214.88M | 16.56%272.18M | -25.83%179.87M |
Cost of revenue | 28.62%211.55M | 16.15%830.15M | 44.07%257.15M | -13.03%210.66M | 35.72%197.87M | 10.95%164.48M | 15.62%714.75M | 26.56%178.49M | 50.98%242.23M | 4.07%145.79M |
Gross profit | 79.29%95.04M | 160.28%364.39M | 398.93%181.57M | 110.69%63.1M | 95.77%66.71M | 33.93%53.01M | -61.86%140M | -44.99%36.39M | -59.01%29.95M | -66.73%34.08M |
Operating expense | 23.14%58.13M | 6.15%191.45M | 9.45%50.06M | -4.88%47.53M | 6.83%46.65M | 15.22%47.21M | 19.44%180.35M | 24.54%45.74M | 31.44%49.97M | 8.54%43.66M |
Selling and administrative expenses | 11.19%28.35M | 0.14%107.54M | -0.25%28.29M | -11.37%28.73M | 0.12%25.02M | 17.97%25.5M | 27.04%107.38M | 31.09%28.36M | 47.07%32.42M | 13.89%24.99M |
-General and administrative expense | 11.19%28.35M | 0.14%107.54M | -0.25%28.29M | -11.37%28.73M | 0.12%25.02M | 17.97%25.5M | 27.04%107.38M | 31.09%28.36M | 47.07%32.42M | 13.89%24.99M |
Depreciation amortization depletion | 17.01%2.78M | 25.57%10.44M | 23.50%2.83M | 39.13%2.8M | 25.72%2.43M | 14.57%2.38M | 4.29%8.32M | 5.37%2.29M | 5.01%2.01M | 5.16%1.94M |
-Depreciation and amortization | 17.01%2.78M | 25.57%10.44M | 23.50%2.83M | 39.13%2.8M | 25.72%2.43M | 14.57%2.38M | 4.29%8.32M | 5.37%2.29M | 5.01%2.01M | 5.16%1.94M |
Other operating expenses | 39.65%27M | 13.64%73.47M | 25.54%18.94M | 2.95%16M | 14.67%19.19M | 11.86%19.34M | 10.51%64.65M | 16.81%15.09M | 10.55%15.55M | 1.76%16.73M |
Operating profit | 536.19%36.91M | 528.59%172.95M | 1,506.69%131.51M | 177.72%15.56M | 309.35%20.07M | 517.11%5.8M | -118.67%-40.35M | -131.77%-9.35M | -157.14%-20.03M | -115.41%-9.59M |
Net non-operating interest income expense | ||||||||||
Other net income (expense) | 45.21%6.14M | 105.86%23.07M | 17.30%6.04M | 11.59%11.1M | 130.34%1.71M | 142.21%4.23M | 4,993.18%11.21M | 78.89%5.15M | 278.78%9.94M | -84.80%-5.63M |
Other non- operating income (expenses) | 45.21%6.14M | 105.86%23.07M | 17.30%6.04M | 11.59%11.1M | 130.34%1.71M | 142.21%4.23M | 4,993.18%11.21M | 78.89%5.15M | 278.78%9.94M | -84.80%-5.63M |
Income before tax | 329.20%43.05M | 772.49%196.01M | 3,371.79%137.55M | 364.40%26.66M | 243.12%21.78M | 2,725.63%10.03M | -113.47%-29.15M | -113.02%-4.2M | -126.76%-10.08M | -125.72%-15.22M |
Income tax | -43.84%-10.72M | 2,829.68%44.52M | 1,568.19%37.7M | 476.91%7.42M | 448.15%6.86M | -132.36%-7.45M | -103.42%-1.63M | -76.53%2.26M | -85.89%1.29M | -112.87%-1.97M |
Net income | 207.55%53.78M | 650.56%151.49M | 1,644.63%99.85M | 269.23%19.24M | 212.65%14.92M | 390.74%17.49M | -116.31%-27.52M | -128.51%-6.46M | -139.81%-11.37M | -130.20%-13.25M |
Net income continuous Operations | 207.55%53.78M | 650.56%151.49M | 1,644.63%99.85M | 269.23%19.24M | 212.65%14.92M | 390.74%17.49M | -116.31%-27.52M | -128.51%-6.46M | -139.81%-11.37M | -130.20%-13.25M |
Minority interest income | 281.61%3.51M | 649.40%15.47M | 1,399.25%10.45M | 468.29%2.35M | 238.36%1.76M | 992.23%919K | -115.36%-2.82M | -130.72%-804K | -121.62%-637K | -125.99%-1.27M |
Net income attributable to the parent company | 203.44%50.27M | 650.69%136.02M | 1,679.49%89.4M | 257.42%16.89M | 209.91%13.16M | 351.88%16.57M | -116.43%-24.7M | -128.22%-5.66M | -141.90%-10.73M | -130.73%-11.97M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 203.44%50.27M | 650.69%136.02M | 1,679.49%89.4M | 257.42%16.89M | 209.91%13.16M | 351.88%16.57M | -116.43%-24.7M | -128.22%-5.66M | -141.90%-10.73M | -130.73%-11.97M |
Basic earnings per share | 183.33%0.68 | 625.00%1.89 | 1,637.50%1.23 | 243.75%0.23 | 205.88%0.18 | 380.00%0.24 | -115.72%-0.36 | -126.67%-0.08 | -141.03%-0.16 | -128.81%-0.17 |
Diluted earnings per share | 190.91%0.64 | 594.44%1.78 | 1,537.50%1.15 | 237.50%0.22 | 200.00%0.17 | 340.00%0.22 | -116.82%-0.36 | -128.57%-0.08 | -143.24%-0.16 | -130.36%-0.17 |
Dividend per share | 8.33%0.65 | 0.00%2.4 | 0.00%0.6 | 0.00%0.6 | 0.00%0.6 | 0.00%0.6 | 0.00%2.4 | 0.00%0.6 | 0.00%0.6 | 0.00%0.6 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |